ECHO-7
Group of viruses
ECHO-7 (trade name Rigvir) is a wild type member of the echovirus group of viruses. It was formerly approved as a virotherapy medication by the State Agency of Medicines of the Republic of Latvia (2004–19). In March 2019, laboratory tests found the medicine to contain far smaller quantities of ECHO-7 virus than its manufacturer claimed. On May 31, 2019, the State Agency of Medicines suspended the registration licence of ECHO-7.
History
The potential use of echovirus as an oncolytic virus to treat cancer was discovered by Latvian scientist and immunologist Aina Muceniece in the 1960s and 1970s. The virus was obtained from intestinal tract of a healthy children and has not been genetically modified. She was an honorary member of the Latvian Association of Oncologists and the founder of The Aina Muceniece Virotherapy Foundation.
Approval
The data used to register the drug in Latvia is not sufficient to obtain approval to use it in the US, Europe, or Japan. As of 2017 there was no good evidence that ECHO-7 is an effective cancer treatment.
Oncologists and other medical experts in Latvia have repeatedly expressed the concern for the lack of clinical trials and evidence of efficacy, as well as unethical advertising.
“ECHO-7” enters the record as group of viruses. Crown Archives preserves that source wording while asking what ECHO-7, Group and viruses can confirm, complicate or overturn.
Why this record matters
“ECHO-7” is worth following because a concise public description often conceals a longer documentary argument. Here, ECHO-7, Group and viruses provides the most credible route into that argument.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated May 6, 2026. The linked authority identifier is Q7276779. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2004, 2019 and 2017.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “ECHO-7”, its source revision and the description used here.
- Expand the search: follow ECHO-7 primary sources, ECHO-7 archive and ECHO-7 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “ECHO-7”?
- Which institution is responsible for the underlying evidence?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “ECHO-7” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.